I'm a little confused. Bruno is saying ' the mean atrophy rate observed in the placebo group is in the upper range of what one would expect in mild AD subjects (Kaye et al., 2005). ' That's based on a 35% reduction level.
Your saying that the results were 45% below AIBL longitudinal results.
So the line up would be PBT2 -2.6%, Placebo -4%, AIBL -4.7%. The AIBL longitudinal result is further away from the upper range of what one would expect in mild AD subjects (according to Bruno and Kaye)?
Am I missing something?
- Forums
- ASX - By Stock
- Hippocampal Atrophy Reduction - Importance
I'm a little confused. Bruno is saying ' the mean atrophy rate...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $34 | 10K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 17196248 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 130790145 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 17196248 | 0.003 |
64 | 88003179 | 0.002 |
28 | 140710099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 129653155 | 26 |
0.005 | 18848455 | 22 |
0.006 | 22089363 | 18 |
0.007 | 54073650 | 25 |
0.008 | 42418463 | 31 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
ATH (ASX) Chart |